Thesis (M.S.)--University of Wisconsin-Madison, 1993. / Typescript. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (leaves 43-47).

Thesis (Ph. D.)--University of Washington, 1996. / Includes bibliographical references (leaves [62]-68).

Thesis (Ph. D.)--University of Washington, 1997. / Vita. Includes bibliographical references (leaves 75-85).

Thesis (Ph. D.)--University of Washington, 1999. / Vita. Includes bibliographical references (leaves 102-113).

Thesis (Ph. D.)--University of Washington, 1996. / Vita. Includes bibliographical references (leaves [56]-64).

Class of 2006 Abstract / Objectives: To create a conversion chart of non-oral estrogen replacement systems based on Cavg. Design: Meta-analysis. Methods: A literature search using two databases, drug manufacturer data, and the online FDA new drug application website was performed in May 2005. Of the original studies identified, those that were selected for analysis met the following inclusion criteria: 1) English in language 2) only included human subjects 3) reported the average blood concentration (Cavg) and 4) were not baseline adjusted. The Cavg data was entered into a spreadsheet and analyzed by an independent statistician. Results: Fifty studies were originally identified. Of these 50 studies, only 22 met inclusion criteria and were used to calculate the mean Cavg of different administration systems. The Cavgs were then used to create a comparison chart. Conclusions: Overall, there has been little research done that examines blood estradiol levels achieved through non-oral administration routes. The chart created from this meta-analysis is vital to health care providers because it allows a patient to be converted from one route to another while assuring the provider that the patient is receiving the same therapeutic benefit.

Diss. Linköping : Univ., 2006.

published_or_final_version / Pharmacology / Doctoral / Doctor of Philosophy

Christopher John Haines. / Thesis (M.D.)--Chinese University of Hong Kong, 1996. / Includes bibliographical references (leaves 239-279). / LIST OF TABLES --- p.xviii / LIST OF FIGURES --- p.xxi / LIST OF ABBREVIATIONS --- p.xxii / Chapter CHAPTER1 --- INTRODUCTION --- p.1 / Problems related to the menopause / Research plan / Chapter CHAPTER2 --- OVERVIEW --- p.15 / Introduction / Atherosclerosis and the lipid profile / Coronary artery disease and lipid abnormalities in women / "Exogenous oestrogens, progestogens and coronary artery disease " / Lipoprotein (a) / Chapter CHAPTER3 --- GENERAL METHODOLOGY --- p.134 / Recruitment of cases / Pharmacokinetics / Data collection and analysis of samples / Ethical considerations / Chapter CHAPTER4 --- STUDY I -THE SHORT TERM EFFECTS OF ORAL OESTROGEN --- p.157 / Crossover analysis of effects of oral oestrogen on lipoprotein (a) and other lipoproteins / Relationship between lipoprotein (a) and other lipids and lipoproteins / Chapter CHAPTER5 --- STUDY II -THE SUSTAINED EFFECTS OF ORAL OESTROGEN --- p.186 / Analysis of prolonged effects of oral oestrogen on lipoprotein (a) and other lipids and lipoproteins / Chapter CHAPTER6 --- STUDY III -THE EFFECTS OF COMBINED CYCLICAL HORMONE REPLACEMENT THERAPY --- p.196 / Analysis of effect of combined cyclical hormone replacement therapy on lipoprotein (a) and other lipids and lipoproteins / Comparison between sampling during oestrogen alone and combined phase of treatment / Chapter CHAPTER7 --- STUDY IV -THE EFFECTS OF PERCUTANEOUS OESTROGEN --- p.214 / Analysis of effect of percutaneous on lipoprotein (a) and other lipids and lipoproteins / Chapter CHAPTER8 --- SUMMARY AND CONCLUSIONS --- p.228 / BIBLIOGRAPHY --- p.239

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 5 uppsatser.